📰 Global Phase News
Page 4 - Global Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Global Phase. Real-time updates on events, politics, business and more.
August 9, 2023
Strengthened Clinical and Regulatory Leadership Team with Key AppointmentsStart-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinic...
June 2, 2023
LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS CANbridge to Hold Investor CallBEIJING & BURLINGTON, Mass. ...
June 1, 2023
- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
June 1, 2023
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor... | June 1, 2023
May 19, 2023
An FDA panel strongly endorsed Thursday that it could be the first maternal respiratory syncytial virus (RSV) vaccine approved to protect infants from the annual epidemic. All 14 members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to conclude that the available data suggest that Pfizer’s RSV prefusion F administered […]
April 27, 2023
-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for... | April 27, 2023
April 24, 2023
Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life ... | June 18, 2023
March 27, 2023
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023
March 27, 2023
Data presented at plenary session of Society of Gynecologic Oncology Meeting Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-1/CTLA-4... | March 27, 2023
March 27, 2023
27.03.2023 - Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced results from a cohort of 24 evaluable patients in an expansion of the Company’s Phase 1b study of ... Seite 1